Transgene: proceeds from sale received
Following this transaction, which was expected to be completed by mid-2023, the biotech company (specializing in viral immunotherapies for the treatment of cancer) confirms financial visibility until early 2024.
We anticipate refinancing before the end of the year, in order to extend financial visibility beyond early 2024 and enable the company to pursue its development in line with its strategic plan", commented Invest Securities.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction